Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Curtis Lachowiez, MD
Videos
Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology
Ajai Chari, MD
Videos
Should Additional BCMA Therapy be Utilized After Prior BCMA Treatment for Multiple Myeloma?
07/31/2024
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in...
07/31/2024
Oncology
Ajai Chari, MD
Videos
Should Stem Cell Transplantation be Suggested for Older Patients With Multiple Myeloma?
07/31/2024
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.
Ajai Chari, MD, participated in...
07/31/2024
Oncology
Elizabeth Brem, MD
Videos
Evaluating the Efficacy of R-Mini-CHOP With or Without Oral Azacytidine for Elderly Patients With DLBCL
07/29/2024
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares...
07/29/2024
Oncology
Elizabeth Brem, MD
Videos
CAR T-Cell Therapy vs Other Novel Therapies for Elderly Patients With Relapsed DLBCL
07/29/2024
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates &...
07/29/2024
Oncology
Rahul Banerjee, MD
Videos
Benefits of Utilizing CAR-T in Later Lines of Therapy for Patients With Multiple Myeloma
07/28/2024
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
Amrita Krishnan, MD
Videos
Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?  
07/28/2024
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates &...
07/28/2024
Oncology
Amrita Krishnan, MD
Videos
Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?  
07/28/2024
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates &...
07/28/2024
Oncology
Murali Janakiram, MD, MS
Videos
Should Minimal Residual Disease Guide Therapy for Patients With Multiple Myeloma?
07/28/2024
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
Murali Janakiram, MD, MS
Videos
Should Minimal Residual Disease Guide Therapy for Patients With Multiple Myeloma?
07/28/2024
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology

Advertisement

About

At Great Debates and Updates in Hematologic Malignancies, nationally recognized thought leaders take opposing sides on clinical—and sometimes controversial—topics currently disrupting the practice of hematology and oncology.

Through comprehensive review of the latest clinical advancements in hematologic malignancies, robust audience engagement, and ample discussion, participants will leave equipped with practical implications and applications to put into practice immediately.

Platinum Sponsors

johnson & johnson

 

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use